Compare COTY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COTY | EXAS |
|---|---|---|
| Founded | 1904 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 11.0B |
| IPO Year | 2013 | N/A |
| Metric | COTY | EXAS |
|---|---|---|
| Price | $3.26 | $101.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 20 |
| Target Price | $5.34 | ★ $77.94 |
| AVG Volume (30 Days) | 5.6M | ★ 10.3M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,798,600,000.00 | $3,082,033,000.00 |
| Revenue This Year | $1.90 | $19.40 |
| Revenue Next Year | $2.53 | $13.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $3.12 | $38.81 |
| 52 Week High | $7.71 | $101.95 |
| Indicator | COTY | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 86.91 |
| Support Level | $3.24 | $101.35 |
| Resistance Level | $3.42 | $101.93 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | 0.02 | -1.35 |
| Stochastic Oscillator | 27.54 | 43.00 |
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.